Besponsa and Prograf drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Besponsa (inotuzumab ozogamicin) and Prograf (tacrolimus). Common drug interactions include cytokine release syndrome among females and venoocclusive liver disease among males.

The phase IV clinical study analyzes what interactions people have when they take Besponsa and Prograf. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Besponsa?

Besponsa has active ingredients of inotuzumab ozogamicin. eHealthMe is studying from 801 Besponsa users. Check the latest studies of Besponsa.

What is Prograf?

Prograf has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 42,230 Prograf users. Check the latest studies of Prograf.

On Jul, 04, 2026

31 people who take Besponsa and Prograf together, and have interactions are studied.

What are the common drug interactions of Besponsa and Prograf, by gender? *:

female:

Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Septic shock (shock due to blood infection)
Venoocclusive liver disease (small veins in the liver are obstructed)
Venoocclusive disease (small veins in the liver are obstructed)
Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
Oral disorder (mouth disease)
Pleural effusion (water on the lungs)
Fluid retention (an abnormal accumulation of fluid in the blood)
Hepatic vein occlusion (blockage of the hepatic vein)

male:

Venoocclusive liver disease (small veins in the liver are obstructed)
Engraftment syndrome (inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation)
Alanine aminotransferase increased
Chronic graft versus host disease in skin (damage by immune cells to skin after grafting)
Pneumonia
Platelet count decreased
Fungal infection
Meningitis bacterial (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
Coma hepatic (accumulation in the bloodstream of toxic substances that are normally removed by the liver leads coma)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)

What are the common drug interactions of Besponsa and Prograf, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Fungal infection
Meningitis bacterial (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
Venoocclusive liver disease (small veins in the liver are obstructed)
Pneumonia

10-19:

Engraftment syndrome (inflammatory condition during neutrophil recovery after hematopoietic stem cell transplantation)
Platelet count decreased
Venoocclusive liver disease (small veins in the liver are obstructed)
Coma hepatic (accumulation in the bloodstream of toxic substances that are normally removed by the liver leads coma)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
Hepatic failure (liver failure)
Immune system disorder

20-29:

Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Septic shock (shock due to blood infection)
Venoocclusive disease (small veins in the liver are obstructed)
Venoocclusive liver disease (small veins in the liver are obstructed)
Thrombotic microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury)
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
Oral disorder (mouth disease)
Fluid retention (an abnormal accumulation of fluid in the blood)
Hepatic vein occlusion (blockage of the hepatic vein)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)

30-39:

n/a

40-49:

Neutropenia (an abnormally low number of neutrophils)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)

50-59:

Blood glucose increased
Blood lactate dehydrogenase decreased
Blood lactate dehydrogenase increased
Blood potassium decreased
Blood urea decreased
Blood urea increased
C-reactive protein increased
Diarrhoea
Gamma-glutamyltransferase increased
Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)

60+:

Alanine aminotransferase increased
Chronic graft versus host disease in skin (damage by immune cells to skin after grafting)

What are the existing conditions these people have? *

Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 19 people, 61.29%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 9 people, 29.03%
B Precursor Type Acute Leukaemia (lymphoid cancer): 6 people, 19.35%
Immunodeficiency Disorders: 6 people, 19.35%
Pain: 4 people, 12.90%
Febrile Neutropenia (fever with reduced white blood cells): 4 people, 12.90%
Constipation: 4 people, 12.90%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 4 people, 12.90%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 4 people, 12.90%
Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 3 people, 9.68%

* Approximation only. Some reports may have incomplete information.

Do you take Besponsa and Prograf?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously